A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1RecruitingNCT06626919

Arcellx, Inc.30 enrolled

Overview

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

This is a Phase 1 open-label, multi-center safety and dose-escalation study of anito-cel\* in adult subjects with GMG (MGFA Grade 2 to 4a), in whom immunosuppressive therapy is clinically indicated in the judgement of the treating neurologist. The primary objective of this study is to assess the safety profile, including any DLT and identification of a MTD (if applicable), to support selection of the RP2D of anito-cel when administered to subjects with GMG. The study will have the following sequential phases: screening, enrollment (leukapheresis), pretreatment with lymphodepletion (LD) chemotherapy, treatment with anito-cel and follow-up. Optional bridging therapy is allowed at investigator discretion while anito-cel is being manufactured. Following a single infusion of anito-cel both safety and efficacy data will be assessed. The DLTs will be assessed in the first 28 days following anito-cel administration, and safety data will be collected throughout the study. \*Anitocabtagene autoleucel (anito-cel) drug product consists of autologous T cells that have been genetically modified ex vivo to express a D-domain Chimeric Antigen Receptor (CAR), followed by a cluster of differentiation 8 (CD8) hinge and transmembrane region that is fused to the intracellular signaling domains for 4-1BB and CD3ξ, that specifically recognizes B-cell maturation antigen (BCMA). The active substance of anitocabtagene autoleucel is CAR+ CD3+ T cells that have undergone ex vivo T-cell activation, gene transfer by replication-deficient lentiviral vector, and expansion.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject must be 18 years of age or older * Must have MGFA clinical classification Grades 2-4A at time of screening * Subject must have clinically active disease and requiring ongoing therapy for GMG * MG-ADL score 6 and QMG score \>10 at screening * GMG specific autoantibodies must be above the reference laboratory ULN Exclusion Criteria: * Subject is pregnant or breastfeeding * Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion * Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager * Previous thymectomy within 6 months of screening * Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator

Locations (9)

UCLA Medical Center

Los Angeles, California, United States

RECRUITING

University of California, Irvine

Orange, California, United States

RECRUITING

Stanford Hospital

Palo Alto, California, United States

RECRUITING

Karmanos Cancer Institute

Detroit, Michigan, United States

RECRUITING

Columbia University Irving Medical Center

New York, New York, United States

RECRUITING

Ohio State University

Columbus, Ohio, United States

RECRUITING

Oregon Health & Science University (OHSU)

Portland, Oregon, United States

RECRUITING

Temple University Hospital

Philadelphia, Pennsylvania, United States

RECRUITING

Houston Methodist Hospital

Houston, Texas, United States

RECRUITING

Outcomes

Primary Outcomes

Assess safety profile, including any DLT and MTD (if applicable)

Type, incidence, and severity of treatment-emergent adverse events (TEAEs), including DLT(s) and laboratory abnormalities

Time frame: 24 months

Selection of RP2D

Evaluate the MTD and establish the RP2D

Time frame: 24 months

Secondary Outcomes

Quantify Clinical Effect of Anito-cel in the Myasthenia Gravis Activities of Daily Living (MG ADL) score

The proportion of subjects achieving a ≥2-point change in the MG ADL score from Baseline at any timepoint after treatment. The MG-ADL is an 8-item patient-reported outcome measure assessing GMG symptoms and functional activities related to activities of daily living and producing a total score ranging from 0 to 24, where higher scores indicate greater severity of disease symptoms.

Time frame: 24 months

Quantify Clinical Effect of Anito-cel in the Quantitative Myasthenia Gravis (QMG) score

The proportion of subjects achieving a ≥3-point change in the QMG from Baseline at any timepoint after treatment. The QMG score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicate greater disease severity.

Time frame: 24 months

Quantify Clinical Effect of Anito-cel in the Myasthenia Gravis Composite (MGC) scale.

The proportion of subjects achieving a ≥3-point change in the MGC score from Baseline at any timepoint after treatment. The MGC is a 10-item assessment that measures signs and symptoms of GMG based on physical examination findings and patient history. The total score ranges from 0 to 50, where higher scores indicate more severe impairment.

Time frame: 24 months

Mean change in QMG score

The mean change in the QMG score from Baseline at any timepoint after treatment. The QMG score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicate greater disease severity.

Time frame: 24 months

Mean change in MG-ADL score

The mean change in the MG-ADLscore from Baseline at any timepoint after treatment. The MG-ADL is an 8-item patient-reported outcome measure assessing GMG symptoms and functional activities related to activities of daily living and producing a total score ranging from 0 to 24, where higher scores indicate greater severity of disease symptoms.

Time frame: 24 months

Mean change in MCG score

The mean change in the MGC score from Baseline at any timepoint after treatment. The MGC is a 10-item assessment that measures signs and symptoms of GMG based on physical examination findings and patient history. The total score ranges from 0 to 50, where higher scores indicate more severe impairment.

Time frame: 24 months

Mean change in MG-QoL15R score

The mean change in the MG QoL15R score from Baseline at any timepoint after treatment. The MG-QoL15 is a 15-item questionnaire that allows clinicians to estimate a patient's quality of life relevant to GMG. The cumulative scores range from 0 to 60, with higher scores representing decreased quality of life.

Time frame: 24 months

Change in titer of myasthenia specific autoantibodies

The proportion of subjects achieving ≥50% reduction in myasthenia-specific autoantibody titers from Baseline at any timepoint after treatment

Time frame: 24 months

PK Parameter for anito-cel: Cmax

Cmax is defined as the maximum observed concentration of anitocel measured/quantified using vector copy number (VCN) on peripheral blood mononuclear cells

Time frame: Day 1 up to 24 months

PK Parameter for anito-cel: Tmax

Tmax is defined as the time (observed time point) of Cmax of anitocel measured/quantified using vector copy number (VCN) on peripheral blood mononuclear cells

Time frame: Day 1 up to 24 months

PK Parameter for anito-cel: Area under the curve (AUC)

AUC is a measure of the anitocel concentration in the blood measured/quantified using VCN on peripheral blood mononuclear cells over time.

Time frame: Day 1 up to 24 months

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Overview

Conditions

Interventions

Eligibility

Locations (9)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts